文献速递主动脉疾病

GLP-1受体激动剂降低腹主动脉瘤破裂、心脏事件及死亡风险

GLP-1 Receptor Agonists Decrease the Rate of Rupture, Cardiac Events, and Death in Patients with Abdominal Aortic Aneurysms.
PubMed 文献 · J Vasc Surg · 2026-10-29

基于TriNetX网络412490例接受6个月影像监测的腹主动脉瘤患者,倾向性评分1:1匹配后比较GLP-1受体激动剂组与非暴露组各13722例。GLP-1RA组2年和5年破裂率、择期修复率及MACE和全因死亡率均显著降低,多因素分析5年风险比均小于1。

要点

  • GLP-1RA与腹主动脉瘤患者5年破裂风险降低相关(HR 0.538)。
  • GLP-1RA与5年全因死亡风险降低相关(HR 0.474)。
  • GLP-1RA组择期修复率和MACE风险亦显著降低。

核心结论

  • 腹主动脉瘤患者使用GLP-1RA与更少的破裂、择期修复及改善的MACE和死亡 rates 相关。
  • 前瞻性分析可能进一步阐明GLP-1RA是否应处方以降低动脉瘤增长率。

研究设计与样本

  • 数据来源于TriNetX研究网络,涵盖123个医疗组织。
  • 采用ICD-10和CPT代码识别每6个月接受腹部影像学的腹主动脉瘤患者。
  • 倾向性评分1:1匹配,协变量包括年龄、性别、糖尿病、二甲双胍使用、高血压、心脏病、吸烟、慢性肾病和肺部疾病。
  • 匹配后GLP-1RA组和非暴露组各13722例。

主要发现

  • GLP-1RA组2年择期修复率1.5% vs 2.3%,5年2.1% vs 3.0%,P<.01。
  • GLP-1RA组2年破裂率1.1% vs 1.8%,5年1.6% vs 2.4%,P<.01。
  • GLP-1RA组2年和5年MACE及全因死亡率显著更少。
  • 多因素分析5年择期修复HR 0.757(95%CI 0.636-0.902),P<.01。
  • 多因素分析5年破裂HR 0.538(95%CI 0.418-0.691),P<.01;全因死亡HR 0.474(95%CI 0.439-0.511),P<.001;MACE HR 0.825(95%CI 0.794-0.857),P<.01。

临床怎么用

  • 对于合并糖尿病的腹主动脉瘤患者,GLP-1RA可能作为兼顾心血管保护与动脉瘤风险控制的降糖选择。
  • 需结合个体化评估,不能仅依据本回顾性研究改变腹主动脉瘤监测或修复指征。

局限性

  • 回顾性观察性设计,可能存在残余混杂。
  • 仅纳入每6个月接受腹部影像学的患者,选择偏倚可能存在。
  • 无法确定GLP-1RA对动脉瘤增长率的因果影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Abdominal aortic aneurysm (AAA) is a degenerative condition involving several processes including inflammation, matrix remodeling, disruptions of vascular smooth muscle cells, and thrombus formation all leading to progressive dilatation of the aorta and eventual rupture. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are now considered part of the frontline therapeutic options to treat type 2 diabetes mellitus and have also been validated as having compelling anti-inflammatory and cardiovascular protective properties. Data is limited on the impact of GLP-1RA on outcomes of patients with AAA. The aim of this study is to examine the association and possible impact of GLP-1RA on patients with AAA. METHODS: Data was sourced from the TriNetX research network, encompassing 123 health care organizations. Utilizing ICD-10 and CPT codes, we identified patients with AAA who received abdominal imaging every six months. Group 1 was comprised of patients who were treated with GLP-1RA while Group 2 patients were not. Propensity-score-matching (PSM) was used in a 1:1 fashion using age, sex, diabetes, metformin use, hypertension, cardiac disease, tobacco use, chronic kidney disease, and pulmonary disease as covariates. Primary outcomes were aneurysm rupture or repair. Secondary outcomes include mortality and major adverse cardiac events (MACE; myocardial infarction, stroke, and heart failure). Standard statistical methods were used as appropriate. RESULTS: We identified 412,490 patients with diagnosis of AAA who were undergoing 6-month surveillance between June 1, 2010 and April 16, 2024. After PSM, the GLP-1RA group (N=13,722) underwent fewer elective repairs at each timepoint (1.5% vs 2.3% at 2 years, 2.1% vs 3.0% at 5 years, P<.01) and had significantly fewer ruptures at two years (1.1% vs 1.8%, P<.01) and five years (1.6% vs 2.4%, P<.01) when compared to Group 2 (N=13,722). Group 1 also experienced significantly fewer MACE and all-cause mortality at two and five years. On multivariate analysis, GLP-1RA significantly reduced the risk of undergoing elective repair (HR 0.757, 95% CI [0.636-0.902], P<.01), rupture (HR 0.538, 95% CI [0.418-0.691], P<.01), all-cause mortality (HR 0.474, 95% CI [0.439-0.511], P<.001), and MACE (HR 0.825, 95% CI [0.794-0.857], P<.01) at 5 years. CONCLUSIONS: The use of GLP-1RA in patients with AAA is associated with fewer ruptures, elective repairs, and improved rates of MACE and death. A prospective analysis may further elucidate if GLP-1RA should be prescribed to reduce the rate of aneurysm growth.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Go CC, Alcantara ACM, Annie F, et al. GLP-1 Receptor Agonists Decrease the Rate of Rupture, Cardiac Events, and Death in Patients with Abdominal Aortic Aneurysms. J Vasc Surg. 2026. PMID: 42957066. doi:10.1016/j.jvs.2026.09.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。